European Neuropsychopharmacology最新文献

{"title":"Frequency, correlates and outcomes of Benzodiazepine use during Cariprazine treatment: A pooled post-hoc analysis from four 6-week, placebo-controlled trials in patients with an acute exacerbation of schizophrenia","authors":"Christoph U. Correll ,&nbsp;Réka Csehi ,&nbsp;Károly Acsai ,&nbsp;Ágota Barabássy","doi":"10.1016/j.euroneuro.2025.02.010","DOIUrl":"10.1016/j.euroneuro.2025.02.010","url":null,"abstract":"<div><div>Given the frequent prescription of benzodiazepines (BZDs) as adjunctive treatment to antipsychotics, this study aimed to uncover how BZD use affects treatment outcomes with cariprazine (CAR).</div><div>This post-hoc analysis used pooled data from four placebo-controlled trials in patients with acute schizophrenia. Efficacy evaluations involved changes from baseline to Week 6 on PANSS Total Score, Marder Positive Factor Score, Excitement Component Subscale Score, and Marder Anxiety Single Item Score. Safety evaluations focused on extrapyramidal symptoms and akathisia. Comparisons were made between CAR alone vs. placebo (PLB) alone; CAR+BZD vs. PLB+BZD; CAR alone vs. CAR+BZD; and PLB alone vs. PLB+BZD.</div><div>Data from 1643 patients were analysed (CAR only=943; CAR+BZD=132; PLB only=475; PLB+BZD=93). CAR alone yielded significantly greater improvement on all measures than PLB alone. CAR+BZD yielded significantly greater improvements in overall schizophrenia symptoms than PLB+BZD. CAR alone showed greater improvements in overall, positive, and anxiety symptoms compared to CAR+BZD. PLB alone yielded significantly greater improvements in positive and anxiety symptoms than PLB+BZD. Anxiety and agitation were the leading reasons for BZD administration. CAR was associated with more akathisia and EPS in both the non-BZD and BZD-user groups than PLB.</div><div>The results support the superior efficacy of CAR with or without BZD co-treatment for total and positive symptoms of schizophrenia compared to PLB with or without BZD use. These findings suggest BZDs should be used for emergent symptoms like anxiety or agitation, rather than core schizophrenia symptoms.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 76-83"},"PeriodicalIF":6.1,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: Premature conclusions on antipsychotic continuation in environmentally conscious psychopharmacotherapy","authors":"Matthias Brunn ,&nbsp;Fabrice Berna","doi":"10.1016/j.euroneuro.2025.03.002","DOIUrl":"10.1016/j.euroneuro.2025.03.002","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Page 6"},"PeriodicalIF":6.1,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143610331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular vesicles in mood disorders: A systematic review of human studies","authors":"Cristian-Daniel Llach ,&nbsp;Gia Han Le ,&nbsp;Sebastian Badulescu ,&nbsp;Gerard Anmella ,&nbsp;Hayder Ali Hasan ,&nbsp;Anna Giménez-Palomo ,&nbsp;Isabella Pacchiarotti ,&nbsp;Eduard Vieta ,&nbsp;Roger S. McIntyre ,&nbsp;Joshua D. Rosenblat ,&nbsp;Rodrigo B. Mansur","doi":"10.1016/j.euroneuro.2025.02.009","DOIUrl":"10.1016/j.euroneuro.2025.02.009","url":null,"abstract":"<div><div>Extracellular vesicles (EVs) are small, membrane-bound particles that are naturally released by nearly all cell types in the body. They serve as molecular biosignatures, reflecting the state of their cells of origin and providing a non-invasive peripheral marker of central nervous system (CNS) activity under physiological and pathological conditions. We conducted a systematic review (ID: CRD42024528824) of studies investigating the use of EVs in mood disorders within clinical populations. We screened articles indexed in PubMed, EMBASE, Scopus, ISI Web of Science, and APA PsycInfo from January 2010 to October 2024. Available research has focused on four key areas: (1) EV cargo as mechanistic and diagnostic biomarkers; (2) EV cargo as predictive or tracking biomarkers for antidepressant response; (3) EV cargo and neuroimaging correlates; and (4) EV physical properties. Most studies examined major depressive disorder (MDD), with others addressing bipolar disorder (BD), adolescent depression, postpartum depression, and late-life depression. Notably, only 35,55 % of the studies utilized brain-derived EVs. Through analyses of EV-derived miRNA, proteins, mtDNA, and metabolites, these studies have explored neural mitochondrial function, brain insulin resistance, neurogenesis, neuroinflammation, and blood-brain barrier permeability in the context of mood disorders. Some EV-derived markers demonstrated diagnostic and predictive potential. This review discusses key findings, limitations of current research, and future directions for leveraging EVs in the study of mood disorders.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 59-75"},"PeriodicalIF":6.1,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COSMIN systematic review and meta-analysis of the measurement properties of the PANSS-6","authors":"Simon Geck ,&nbsp;Maximilian Roithmeier ,&nbsp;Markus Bühner ,&nbsp;Sophia Wehr ,&nbsp;Lucia Weigel ,&nbsp;Josef Priller ,&nbsp;John M. Davis ,&nbsp;Stefan Leucht","doi":"10.1016/j.euroneuro.2025.02.008","DOIUrl":"10.1016/j.euroneuro.2025.02.008","url":null,"abstract":"<div><div>The Positive and Negative Syndrome Scale (PANSS-30) is the standard instrument for assessing symptoms of schizophrenia and related psychotic disorders. However, its long administration time and structural issues have prompted the development of shorter versions. The PANSS-6, derived through Item Response Theory and Rasch analysis of the PANSS-8, emerged as a potential alternative. Comprising three positive and three negative symptom items, the PANSS-6 offers a more feasible assessment tool. However, its measurement properties have never been systematically reviewed.</div><div>We applied the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guideline for systematic reviews and meta-analytical procedures to assess the psychometric properties of the PANSS-6. COSMIN comprises several steps: literature search, risk-of-bias assessments, assessing the updated criteria for good measurement properties, grading the quality of the evidence and feasibility aspects.</div><div>We included 13 publications. The PANSS-6 showed sufficient content validity, structural validity, measurement invariance, reliability, criterion validity, construct validity and responsiveness according to COSMIN. On some of them only a small body of evidence is currently available. For internal consistency, cross-cultural validity and measurement error there was not enough evidence for a definite rating. Its short administration time of only 15–20 mins renders feasibility good.</div><div>The PANSS-6 does not cover all schizophrenia symptoms but focuses on the core symptoms in favor of a feasible administration time. The evidence available on its measurement properties yields sufficient results for its purpose - the assessment of symptom severity and its change. According to COSMIN it can potentially be recommended for use.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 41-50"},"PeriodicalIF":6.1,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ketamine addiction in Europe: Any risks on the horizons?","authors":"Francesco Bavato ,&nbsp;Boris B. Quednow","doi":"10.1016/j.euroneuro.2025.02.015","DOIUrl":"10.1016/j.euroneuro.2025.02.015","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 39-40"},"PeriodicalIF":6.1,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscarinic acetylcholine receptor agonists in bipolar disorder","authors":"Meritxell González-Campos ,&nbsp;Eduard Vieta","doi":"10.1016/j.euroneuro.2025.03.001","DOIUrl":"10.1016/j.euroneuro.2025.03.001","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 4-5"},"PeriodicalIF":6.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical drug development: Seeking to improve the reproducibility of results from behavioural experiments in animals","authors":"Ines Erkizia-Santamaria ,&nbsp;J. Javier Meana ,&nbsp;Jorge E. Ortega","doi":"10.1016/j.euroneuro.2025.02.014","DOIUrl":"10.1016/j.euroneuro.2025.02.014","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Pages 2-3"},"PeriodicalIF":6.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis","authors":"Jing Tian ,&nbsp;Spyridon Siafis ,&nbsp;Xiao Lin ,&nbsp;Hui Wu ,&nbsp;Schneider-Thoma Johannes ,&nbsp;Leucht Stefan","doi":"10.1016/j.euroneuro.2025.02.012","DOIUrl":"10.1016/j.euroneuro.2025.02.012","url":null,"abstract":"<div><h3>Background</h3><div>High discontinuation rates compromise the effectiveness of treatment regimens for schizophrenia, because consistent medication adherence is essential for the efficacy of antipsychotics. Understanding the relationship between antipsychotic doses and discontinuation rates is important. This study explores this relationship to identify doses that maximize treatment adherence and minimize discontinuation.</div></div><div><h3>Methods</h3><div>We systematically searched multiple electronic databases for fixed-dose RCTs assessing 20 antipsychotics in patients with acute exacerbation of schizophrenia and related disorders. We analyzed dose-response relationships using a one-stage dose-response meta-analysis within a frequentist framework, employing restricted cubic splines to model the relationships. The primary outcome was discontinuation for any reason, and secondary outcomes were discontinuation due to inefficacy and side effects.</div></div><div><h3>Results</h3><div>Analysis of 136 trials involving 44,126 participants revealed various dose-response relationships for antipsychotics. For the primary outcome, all-cause discontinuation, amisulpride, cariprazine, olanzapine (Zyprexa), and quetiapine demonstrated U-shaped curves, indicating optimal dosing thresholds where further increases in dosage led to heightened discontinuation rates, possibly due to side effects. Aripiprazole, asenapine, brexpiprazole, clozapine, paliperidone, and risperidone (Risperdal) had plateaus, suggesting no additional benefit from increasing doses beyond specific points. For haloperidol, iloperidone, lumateperone, lurasidone, sertindole, and ziprasidone, the dose-response curves did not reach a plateau within the examined doses. Inefficacy discontinuation curves were similar to total discontinuation. Most discontinuation for side-effects curves showed sharp increases in side-effects associated with higher doses.</div></div><div><h3>Conclusion</h3><div>Dose discontinuation curves varied between the antipsychotics and included U-shaped, monotonic, and hyperbolic patterns. Future studies should consistently present disease-related and side-effect-related dropouts due to adverse events separately.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 51-58"},"PeriodicalIF":6.1,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143579654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic mild stress dysregulates autophagy, membrane dynamics, and lysosomal status in frontal cortex and hippocampus of rats","authors":"Cristina Ulecia-Morón ,&nbsp;Álvaro G. Bris ,&nbsp;Karina S. MacDowell ,&nbsp;Pilar Cerveró-García ,&nbsp;José L.M. Madrigal ,&nbsp;Borja García-Bueno ,&nbsp;Marta P. Pereira ,&nbsp;Juan C. Leza ,&nbsp;Javier R. Caso","doi":"10.1016/j.euroneuro.2025.02.005","DOIUrl":"10.1016/j.euroneuro.2025.02.005","url":null,"abstract":"<div><div>Inflammation has been related to major depressive disorder pathophysiology. Autophagy, a degradative pathway regulating inflammation and immunity, has emerged as a potential contributor. Among others, we characterized, in frontal cortex (FC) and hippocampus (Hp), autophagy markers (upregulations in mTOR, ATG7, and ATG 16L1, and downregulations in ULK1, BECLIN1, phospho-SQSTM1, ATG3, ATG12, and ATG 16L1), effectors of the endosomal sorting complexes required for transport (overexpression in HRS, VPS37A, CHMP6, and GALECTIN 3, and downregulations in STAM2, TSG101, VPS28, VPS37A, CHMP5, VPS4B, and GALECTIN 9), and lysosomal proteins (LAMP1, LAMP2A, MANNOSE RECEPTOR, HSC70, HSP70, CATHEPSIN D and B, and CYSTATIN C, whose variations are dependent on lysosomal nature and brain region) of male rats exposed to chronic mild stress, a model of depression, compared to control rats. Results indicate that chronic stress alters protein expression of autophagy and the endosomal sorting complexes required for transport markers in a region-specific manner, plus increases lysosomal presence, oppositely modulating lysosomal proteins in each structure. Additionally, astrocytes seemed to exert an essential role in the regulation of the autophagy adaptor SQSTM1/p62. In conclusion, stress-induced protein disruptions in these pathways highlight their differential modulation after chronic stress exposure and their potential role in maintaining brain homeostasis during the stress response, making them promising targets for new therapeutic strategies in stress-related pathologies.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"94 ","pages":"Pages 24-35"},"PeriodicalIF":6.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Muscle and the mind: The combination of creatine and exercise for depression","authors":"Nicholas Fabiano ,&nbsp;Brendon Stubbs","doi":"10.1016/j.euroneuro.2025.02.007","DOIUrl":"10.1016/j.euroneuro.2025.02.007","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"95 ","pages":"Page 1"},"PeriodicalIF":6.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143562006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}